Compound class:
Synthetic organic
Comment: LY3509754 is an orally bioavailable, small molecule inhibitor of the proinflammatory cytokine IL-17A [1]. It was intended as an alternative to anti-IL-17A monoclonals for the treatment of psoriasis.
|
|
References |
1. Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, Poorbaugh J, Schmitz C, Wang E, Woodman ME. (2024)
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study. Clin Pharmacol Ther, 115 (5): 1152-1161. [PMID:38294091] |